Clinical Trial Update: A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing single agent melphalan to BEAM as a preparative regimen for high-dose therapy with autologous stem cell reinfusion in multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BEAM regimen (busulfan, cyclophosphamide, etoposide, cytarabine)
• melphalan (single agent) (melphalan)

Snippet

Sponsor: Swedish Medical Center | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN